However, the studies with relatively larger sample sizes (PARADISE-MI [Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction], PARAGON-HF [Prospective Comparison of ARNI with ARB Global Outcomes in Heart Failure with Preserved Ejection Fraction]) showed a statistically nonsignificant reduction in all-cause mortality.6 This evidence concerns the gene ACE and hydrops fetalis.